---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-22-000048"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:48:30.024409+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M

## Summary
- GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).
- FY22 guidance raised: total revenue $655-685M (prior $530-560M); non-GAAP EPS $2.10-2.25.
- Antares Pharma acquisition closed May 2022; expected to add $115-125M revenue in FY22.
- Operating income $34.1M vs $93.0M in Q2 2021, reflecting Antares-related transaction costs.
- Cash and marketable securities $209.4M on June 30, 2022, down from $740.9M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001159036-22-000048
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/0001159036-22-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/halo-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-22-000048
- JSON: https://secwatch.observer/filing/0001159036-22-000048.json
- Plain text: https://secwatch.observer/filing/0001159036-22-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.